Navigation Links
Researchers find genetic tie to improved survival time for pulmonary fibrosis
Date:5/21/2013

AURORA, Colo. (May 21, 2013) Research into genetic features of pulmonary fibrosis by physicians and scientists at the University of Colorado School of Medicine may lead to improved treatment of this deadly lung disease, according to a paper published online by JAMA.

The study found that a particular genetic variation helps predict survival in some cases of pulmonary fibrosis, a chronic progressive disease with a median survival of three years. As a result of the study, researchers may want to consider including genetic testing in future clinical trials.

The researchers looked at whether the MUC5B promoter polymorphism, which previously was found to be associated with developing the disease, is also associated with survival time for individuals with pulmonary fibrosis. MUC5B is a protein that is a component of the mucous produced by the bronchial tubes. Pulmonary fibrosis is a condition where lung tissue becomes thickened, stiff and scarred.

The investigators found that genetic changes in the MUC5B gene are associated with marked improvement in survival among patients with pulmonary fibrosis. This represents the first genetic test that can be used to prognosticate in pulmonary fibrosis and may prove useful taking care of patients with this disease. Currently in the United States, there are no drugs approved for use in cases of the disease. This paper indicates that future drug trials should consider including this genetic test to determine the benefit of their intervention.

The research was supported by funding from the National Heart, Lung and Blood Institute and the Dorothy P. and Richard P. Simmons Endowed Chair for Pulmonary Research at the University of Pittsburgh School of Medicine. Twenty-two authors shared credit for the paper, including researchers from the University of Chicago, the University of Illinois at Chicago, the University of Pittsburgh, Vanderbilt University and InterMune from Brisbane, Calif.

Anna L. Peljto, DrPH, from the Colorado School of Public Health was the first author and David A. Schwartz, MD, chairman of the School of Medicine's Department of Medicine, was the senior author of the paper. Additional authors from Colorado institutions were Tasha E. Fingerlin, PhD, from the Colorado School of Public Health; Lori J. Silveira, PhD, Max A. Seibold, PhD, Kevin K. Brown, MD, and Janet L. Talbert, MS, from National Jewish Health; and Elissa Murphy, MS and Marvin I. Schwarz, MD, from the University of Colorado School of Medicine.

David Schwartz this month gave the American Thoracic Society's Amberson Lecture, an honor bestowed annually on an individual with a career of major lifetime contributions to clinical or basic pulmonary research and/or clinical practice. The JAMA study was released online to coincide with its presentation at the American Thoracic Society's international conference.


'/>"/>

Contact: Mark Couch
mark.couch@ucdenver.edu
303-724-5377
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Leading researchers report on the elusive search for biomarkers in Huntingtons disease
2. Dissertation Clinic Prescribes Customized Remedy for Researchers
3. AGA honors distinguished clinicians, researchers and educators with prestigious recognition awards
4. Moffitt Cancer Center researchers analyze how Spanish smoking relapse booklets are distributed
5. Researchers say they are shocked by new statistics on head injuries among people who are homeless
6. A Premium Service for Researchers Launched in Switzerland
7. Two Leading Alzheimer's Disease Researchers Recognized with MetLife Foundation Awards
8. PolyU Researchers Develop Novel Brain Training Device to Reconnect the Brain and Paralyzed Limb After Stroke
9. University of Colorado Researchers Find Dual Chamber Defibrillators Pose Higher Risk of Complications
10. Leap in leukemia treatment reported by Dartmouth researchers
11. Researchers discover master regulator that drives majority of lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS ... PicoSure. Designed to provide the most effective tattoo removal today, Dr. Bentkover is the ... , Developed by Cynosure, the PicoSure has been approved by the Food and Drug ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the defenses of the day ... feature of patients with eating disorders is significant self-criticism, and consequently these patients experience ... are regarded as maladaptive means for coping with this unease, but also leads to ...
(Date:2/5/2016)... ... February 05, 2016 , ... On June 9-10, Las Vegas ... medical education (CME) event presented by the Association for Comprehensive Care in Rare ... ACCORD, whose mission is to provide education, tools, and resources to primary care ...
(Date:2/5/2016)... ... February 05, 2016 , ... –This week, Atascadero water heater ... having a tankless water heater. To view the report, click here or ... tankless. While each has their pros and cons, the type chosen is almost entirely ...
(Date:2/4/2016)... ... February 04, 2016 , ... Dr. Carol Francis and ... February 19-21, 2016, in Southern California . The International Hypnosis Federation 2016 Conference ... professional speakers, including Clinical Psychologist and Hypnotherapist Dr. Carol Francis (topics ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)...  The Senior Care Pharmacy Coalition (SCPC) today ... Jason Chaffetz (R-UT) and Ranking Member ... , "Developments in the Prescription Drug Market," to ... about abusive pharmacy benefit manager (PBM) pricing practices. ... Member Elijah Cummings (D-MD) are diligent, serious lawmakers ...
(Date:2/4/2016)... , Feb. 4, 2016  Montoya Love is ... in the field of Pharmaceuticals. Montoya is the Regulatory ... Manufacturing and ... Becton Dickinson provides healthcare institutions, clinical laboratories ... throughout fifty countries across the globe. ...
(Date:2/4/2016)... Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... highlights: , Sales in local currency increased ... Reported sales decreased 3% as currency reduced sales growth ... per diluted share as reported (EPS) were $4.44, compared ... was $4.65, an increase of 10% over the prior-year ...
Breaking Medicine Technology: